Targeting Hepcidin to Restore Oral Iron Efficacy After Vertical Sleeve Gastrectomy

Why It Matters

Elevated hepcidin after VSG blocks iron mobilization, rendering standard oral supplementation ineffective and prompting a new therapeutic strategy.

Key Takeaways

• VSG triggers hepcidin surge that blocks ferroportin, trapping iron
• Oral iron fails to raise serum iron despite increased intestinal uptake
• Curcumin suppresses hepatic hepcidin, restores ferroportin, normalizes iron levels
• Patient data shows higher hepcidin correlates with post‑VSG iron deficiency
• Targeting the hepcidin‑ferroportin axis offers a new therapeutic route

Pulse Analysis

Metabolic bariatric surgery, especially vertical sleeve gastrectomy (VSG), is the gold‑standard treatment for severe obesity, yet more than 30 % of patients develop iron deficiency within the first year. Conventional wisdom attributes this anemia to reduced gastric acid and shortened duodenal exposure, assuming impaired iron absorption. Recent work, however, reveals a paradox: VSG actually up‑regulates intestinal iron‑transport proteins such as DMT1 and Dcytb, suggesting that the gut retains the capacity to take up dietary iron. This shift forces clinicians to look beyond absorption and examine systemic regulatory pathways.

The study by Tan et al. demonstrated that VSG‑induced iron deficiency is driven by a disproportionate rise in hepatic hepcidin after oral iron intake. Elevated hepcidin triggers internalization and degradation of ferroportin, the sole iron exporter, causing iron to accumulate in enterocytes, hepatocytes, and macrophages while serum levels remain low. In mouse models, adding 0.4 % curcumin to an iron‑rich diet suppressed hepcidin transcription, rescued ferroportin protein, and restored normal serum iron and transferrin saturation. Parallel human data showed that patients who remained iron‑deficient six months post‑VSG had significantly higher circulating hepcidin, confirming the translational relevance.

These findings reposition post‑VSG anemia as a disorder of iron mobilization rather than simple malabsorption, opening a therapeutic window for hepcidin‑targeted agents. Small‑molecule hepcidin antagonists, monoclonal antibodies, or nutraceuticals like curcumin could be integrated into standard postoperative protocols to enhance the efficacy of oral iron supplements. Larger clinical trials will be needed to define dosing, safety, and long‑term outcomes, but the potential to reduce anemia‑related morbidity could translate into significant cost savings for bariatric programs and improved quality of life for patients.